- Home
- SGHT vs BANX Comparison
SGHT vs BANX Comparison
Compare SGHT & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- BANX
- Stock Information
- Founded
- SGHT 2011
- BANX 2013
- Country
- SGHT United States
- BANX United States
- Employees
- SGHT N/A
- BANX N/A
- Industry
- SGHT Medical Specialities
- BANX Trusts Except Educational Religious and Charitable
- Sector
- SGHT Health Care
- BANX Finance
- Exchange
- SGHT Nasdaq
- BANX Nasdaq
- Market Cap
- SGHT 179.7M
- BANX 146.9M
- IPO Year
- SGHT 2021
- BANX N/A
- Fundamental
- Price
- SGHT $3.69
- BANX $21.11
- Analyst Decision
- SGHT Buy
- BANX
- Analyst Count
- SGHT 8
- BANX 0
- Target Price
- SGHT $4.29
- BANX N/A
- AVG Volume (30 Days)
- SGHT 125.0K
- BANX 23.4K
- Earning Date
- SGHT 11-06-2025
- BANX 06-17-2025
- Dividend Yield
- SGHT N/A
- BANX 9.66%
- EPS Growth
- SGHT N/A
- BANX N/A
- EPS
- SGHT N/A
- BANX 2.35
- Revenue
- SGHT $76,303,000.00
- BANX $29,467,794.00
- Revenue This Year
- SGHT N/A
- BANX N/A
- Revenue Next Year
- SGHT $11.32
- BANX N/A
- P/E Ratio
- SGHT N/A
- BANX $8.88
- Revenue Growth
- SGHT N/A
- BANX 2.73
- 52 Week Low
- SGHT $2.03
- BANX $17.99
- 52 Week High
- SGHT $7.03
- BANX $21.67
- Technical
- Relative Strength Index (RSI)
- SGHT 39.74
- BANX 61.16
- Support Level
- SGHT $4.09
- BANX $20.50
- Resistance Level
- SGHT $4.25
- BANX $20.83
- Average True Range (ATR)
- SGHT 0.16
- BANX 0.31
- MACD
- SGHT -0.07
- BANX 0.04
- Stochastic Oscillator
- SGHT 9.16
- BANX 93.85
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.